CLAIMS

1.- Compound having the general formula (I):

or its geometric isomers, its optically active forms, diastereoisomers, its racemic forms, or its pharmaceutically acceptable salts, wherein R^1 is selected from the group consisting of: C_2 - C_9 alkandiamine, C_2 - C_6 amine; X is selected from the group consisting of: -S-S-, -S-, -CH₂-, -CH₂-CH₂-; m is an integer greater than zero and lower than eight; Ar represents an aromatic group; R^1 comprises a nitrogen linked directly to the carbonyl.

15

20

10

- 2.- Compound according to claim 1, wherein X represents -S-S-.
- 3.- Compound according to claim 1 or 2, wherein m is an integer greater than two and lower than five.
- 4.- Compound according to claim 3, wherein m is four.
- 5.- Compound according to one of the previous claims, wherein Ar presents a formula selected from the group consisting of:

25

30

wherein R^5 is selected from the group consisting of: hydrogen, 35 amine, nitroalkyl, -NH₂, nitro, halogen, hydroxy; R^6 is

5

10

35

selected from the group consisting of: hydrogen, amine, alkandiamine, $-NH_2$; R^7 is selected from the group consisting of: hydrogen, group having an electron attractor inductive effect; R^{13} , R^{14} , R^{15} , R^8 and R^9 are selected, each independently of the others, from the group consisting of: hydrogen, hydroxy, halogen, alkoxy, alkyl, nitroalkyl, cyanoalkyl, nitro, cyano; R^{10} and R^{11} , are selected, each independently of the other, from the group consisting of: hydrogen, C_1-C_4 alkyl; R^{12} represents a C_1-C_4 alkyl; Y is selected from the group consisting of -CH- and -N-.

6.- Compound according to claim 5, wherein Ar presents a formula selected from the group consisting of:

7.- Compound according to claim 6, wherein Ar presents the 20 formula:

- 25 wherein R^1 represents a C_2 - C_6 amine.
- 8.- Compound according to claim 7, wherein R^1 presents the formula $-N(CH_2)_n$ -, wherein the nitrogen is directly linked to the carbonyl and n is an integer greater than one and smaller 30 than five.
 - 9.- Compound according to claim 8, wherein n is three; R^{19} and R^{11} represent, each, a respective methyl; R^{12} represents an ethyl and is linked at the meta position with respect to the oxygen.

10.- Compound according to claim 9, and having the following formula:

11.- Compound according to claim 6, wherein Ar presents the formula:

10

5

wherein Y represents N, R¹ represents an alkandiamine having the formula -NR³-R²-NR⁴-; R² represents a C₂-C₅ alkyl; R³ and R⁴ are selected, each independently of the other, from the group consisting of: hydrogen, methyl; R¹³, R¹⁴, R¹⁵ are selected, each independently of the others, from the group consisting of: hydrogen, hydroxy, halogen, C₁-C₄ alkoxy, C₁-C₄ alkyl.

20

25

- 12.- Compound according to claim 11, wherein R^2 represents a linear propyl; R^3 and R^4 each represent a hydrogen; R^{13} represents a halogen; R^{14} and R^{15} are selected, each independently of the other, from the group consisting of: halogen, hydroxy, C_1 - C_4 alkoxy.
- 13.- Compound according to claim 11 or 12, wherein R^{13} represents a chlorine; R^{14} and R^{15} represent, each, a respective methoxy.

30

35

14.- Compound according to claim 5, wherein Ar presents the formula:

 R^7 is selected from the group consisting of: hydrogen, C_1 - C_4 alkoxy, halogen; R^6 is selected from the group consisting of: -NH₂, alkandiamine, amine; R^1 represents a C_1 amine.

- 5 15.- Compound according to claim 14, wherein R^6 is selected from the group consisting of: $-NH_2$ and amine C_1-C_4 .
- 16.- Compound according to claim 14, wherein R^7 is a chlorine situated in position 6; R^6 represents $-NH_2$; R^1 represents $-NH_2$ 10 CH_2 -, wherein the nitrogen is linked to the carbonylic carbon.
 - 17.- Compound according to claim 5, wherein Ar presents the formula:

15

30

wherein R^1 represents a $C_2\text{--}C_6$ alkandiamine.

- 20 18.- Compound according to claim 17, wherein \mathbb{R}^1 represents a \mathbb{C}_3 - \mathbb{C}_4 alkandiamine.
- 19.- Compound according to claim 17 or 18, wherein R¹ presents the formula -NR³-R²-NR⁴-, wherein R² represents a C₂-C₄ alkyl, R³ and R⁴ are selected, each independently of the other, from the group consisting of: hydrogen, methyl.
 - 20.- Compound according to claim 19, wherein \mathbb{R}^3 and \mathbb{R}^4 represent, each, a respective hydrogen.
 - 21.- Compound according to claim 19 or 20, wherein R^2 represents $-(CH_2)_3-$.
- 22.- Compound according to one of the claims from 17 to 21, wherein R⁷ represents a group having an electron withdrawing inductive effect.

15

30

- 23.- Compound according to claim 22, wherein \mathbb{R}^7 is selected from the group consisting of: halogen, C_1-C_4 alkoxy.
- 5 24.- Compound according to claim 23, wherein R7 represents a halogen.
- 25.- Compound according to one of the claims from 17 to 21, wherein R⁷ is selected from the group consisting of: halogen, hydrogen, methoxy; R⁵ is selected from the group consisting of: hydrogen, amine, nitroalkyl, halogen, hydroxy.
 - 26.- Compound according to one of the claims from 17 to 25, wherein ${\mbox{R}}^7$ is situated in position 6.
 - 27.- Compound according to one of the claims from 17 a 26, wherein R^5 is selected from the group consisting of: hydrogen, C_1 - C_4 amine, C_1 - C_4 nitroalkyl, -NH₂, nitro, halogen.
- 20 28.- Compound according to one of the claims from 17 to 26, wherein \mathbb{R}^5 is selected from the group consisting of: hydrogen, halogen.
- 29.- Compound according to claim 28, and having the following 25 formula:

30.- Compound according to claim 29, in form R:

31.- Compound according to claim 6, wherein Ar presents the formula:

5



wherein R^1 represents a C_3 - C_9 alkandiamine.

10 32.- Compound according to claim 31, wherein \mathbb{R}^1 represents a C_6-C_8 alkandiamine.

33.- Compound according to claim 31 or 32, wherein R^1 presents the formula $-NR^{16}-R^{17}-NR^{18}-R^{19}-$, wherein R^{19} is linked to Ar and $-NR^{16}$ is linked to the carbonylic carbon; R^{17} is a C_2-C_7 alkyl; R^{16} and R^{18} are selected, each independently of the other, from the group consisting of: C_1-C_3 alkyl, hydrogen; R^{19} represents a C_1-C_3 alkyl.

- 34.- Compound according to claim 33, wherein R^{17} is a C_3 - C_6 alkyl; R^{16} represents a hydrogen; R^{18} is selected from the group consisting of: ethyl, methyl, hydrogen; R^{19} represents a methyl.
- 35.- Compound according to one of the claims from 31 a 34, wherein R^9 is selected from the group consisting of: hydrogen, hydroxy, halogen, C_1 - C_4 alkoxy; R^8 is selected from the group: hydroxy, halogen, C_1 - C_4 alkoxy.
- 30 36.- Compound according to claim 35, wherein R⁹ represents a hydrogen and R⁸ represents a methoxy situated in ortho or meta position with respect to the remaining part of the compound.
- 37.- Compound according to claim 36, and having the following 35 formula:

5

- 38.- Compound having the general formula (I), as defined in any one of the claims from 1 to 37, for use as a medicament.
- 39.- Use of a compound having the general formula (I), as defined in any one of the claims from 1 to 37, for the production of a pharmaceutical preparation for the treatment of Alzheimer's disease.
- 40.- Use of a compound having the general formula (I), as defined in any one of the claims from 1 to 37, for the production of a pharmaceutical preparation for the treatment of Alzheimer's disease in mammals.
- 41.- Use of a compound having the general formula (I), as defined in any one of the claims from 1 to 37, for the production of a pharmaceutical preparation for the treatment of pathologies characterised by deposits of β -amiloid (A β) in mammals.
- 25 42.- Pharmaceutical preparation comprising a compound having general formula (I), as defined in any one of the claims from 1 to 37, or a pharmaceutically acceptable salt, and an excipient and/or pharmaceutically acceptable diluent.
- 30 43.- Method for the treatment of Alzheimer's disease in a mammal; the method comprises administering to said mammal an efficacious quantity of a compound having general formula (I), as defined in any one of the claims from 1 to 37.
- 35 44.- Method for the synthesis of a compound having general formula (I), as defined in any one of the claims from 1 to 37,

comprising an addition phase wherein a compound having the general formula (II):

$$\bigvee_{\mathsf{CH}_2)\mathsf{n}} \mathsf{OH}$$

5

is reacted with a compound having the general formula (III):

in basic conditions.

10